PubMed Trending Research Digest — August 15, 2026

Automated digest · 97 articles · 15 research areas · August 15, 2026

Overview

This week’s digest is dominated by precision strategies—both in oncology and in immune-mediated disease—where mechanistic insight is being translated into better patient selection and combination approaches. In cancer, multiple studies emphasize how treatment response is shaped by microenvironmental barriers (e.g., N-glycans suppressing solid-tumor CAR-T function; PGE2-driven NK reprogramming driving PD-1 resistance) and by actionable biomarkers (e.g., spatial epigenetic marks and fibroblast states predicting HER2 ADC response; ctDNA patterns for perioperative nivolumab benefit; SPEN loss as a driver of ARPI resistance). Across prostate, breast, and lung cancer, trial results and biomarker frameworks converge on the same theme: intensify or switch therapy based on disease burden, molecular context, and measurable residual disease signals.

A second major thread is “systems biology” approaches to inflammation and tissue remodeling. Single-cell and spatial omics are used to map immune–stromal crosstalk in lupus nephritis and Crohn’s disease, while metabolic-immune links are explored in sepsis (lactate-driven lysine lactylation) and in obesity-associated inflammation affecting multiple skin diseases. In parallel, neurodegeneration research continues to connect molecular pathology to tractable cellular dysfunction—mitochondrial impairment in tauopathy, RNA surveillance controlling toxic repeat translation in C9orf72 disease, and glial programs (TREM2, PINK1-dependent ensheathing glia) that may help explain early synaptic loss.

Finally, the digest highlights rapid maturation of enabling technologies: improved genome editing prediction/design (OptiPrime; host-factor CRISPR screens; safer nucleic-acid design considerations), advanced single-cell multi-omic profiling, and next-generation delivery platforms (mRNA CAR-T generation via polymer–lipid nanoparticles; engineered EVs for spinal cord injury repair; glucose-sensing living probiotics). Together, these studies suggest a field moving from “what works” toward “why it works,” with increasingly sophisticated tools to measure, predict, and modulate biological systems.

---

Prostate cancer (ADT/ARPI, radiotherapy, resistance, ctDNA/MRD)

SPEN inactivation drives resistance to androgen receptor pathway inhibitors in metastatic prostate cancer.

The study investigated whether SPEN inactivation drives resistance to androgen receptor pathway inhibitors (ARPIs) in metastatic prostate cancer using LNCaP and VCaP cell lines and clinico-genomic data from a nationwide prostate cancer database. It identified SPEN inactivation as a driver of ARPI resistance and used survival analyses (log-rank and Cox models) and SPEN immunohistochemistry on rapid autopsy metastatic tissue (truncated). This is significant because SPEN loss could serve as a biomarker to predict ARPI resistance and guide treatment selection in metastatic prostate cancer.

Blinka S, Arora S, Rudoy D et al. · Clinical cancer research : an official journal of the American Association for Cancer Research · (2026) · View on PubMed ↗

Metabolic Dysfunction After Initiation of Androgen Receptor Pathway Inhibitors in Prostate Cancer.

The study characterized the occurrence, timing, and rate of metabolic syndrome (MetS) and its components during the first year after starting androgen deprivation therapy combined with androgen receptor pathway inhibitors (ADT-ARPI) in men with prostate cancer. Metabolic dysfunction emerged after initiation of ARPI therapy, with patterns varying by age and ARPI type, and component metabolic outcomes were tracked as secondary endpoints. Clinically, the results support early metabolic monitoring and risk mitigation when initiating ARPI-based treatment.

Shaver AL, Zarrabi KK, Nikita N et al. · JAMA oncology · (2026) · View on PubMed ↗

Stereotactic Body Radiotherapy vs Moderately Hypofractionated IMRT for Localized Intermediate-Risk Prostate Cancer: A Randomized Clinical Trial.

The randomized clinical trial compared stereotactic body radiotherapy (SBRT) versus moderately hypofractionated intensity-modulated radiation therapy (MH-IMRT) for localized intermediate-risk prostate cancer, focusing on patient-reported urinary and bowel quality of life and disease-free survival (DFS). SBRT was evaluated for superiority against MH-IMRT in an international phase 3 setting (NRG-GU005), with outcomes including both toxicity-related patient-reported measures and oncologic control. This directly informs radiotherapy selection and scheduling tradeoffs for intermediate-risk prostate cancer.

Ellis RJ, Pugh SL, Yu JB et al. · JAMA · (2026) · View on PubMed ↗

Changes in Muscle Mass and Quality Mediate the Effect of High-Calorie Intake on Clinical Outcomes.

This translational study tested whether early high-calorie intake affects clinical outcomes by altering skeletal muscle mass or quality, combining data from critically ill patients with a 72-hour ventilated piglet model and limb muscle biopsies. The key finding is that changes in muscle mass and muscle quality mediate the relationship between high-calorie intake and clinical outcomes, supported by molecular pathway analyses from biopsies. This supports a mechanistic basis for optimizing early nutrition in critical illness to preserve muscle function and improve outcomes.

Aarab Y, Raynaud F, Capdevila M et al. · Journal of cachexia, sarcopenia and muscle · (2026) · View on PubMed ↗

Bacterial Outer Membrane Vesicle-Based Versatile In Situ Nanovaccine Enhancer Synergized With Radiofrequency Ablation Against Hepatocellular Carcinoma.

This preclinical study developed an outer membrane vesicle (OMV)-based in situ nanovaccine enhancer, OMVbsAb-MAL, for synergy with radiofrequency ablation (RFA) against hepatocellular carcinoma (HCC). The key finding is that OMVbsAb-MAL—engineered with DEC205/PD-L1 bispecific antibodies and maleimide (MAL) to form thioether bonds with tumor proteins after local post-RFA administration—captures tumor-associated antigens in situ and enhances antitumor immune responses to reduce recurrence risk. Clinically, the approach aims to overcome immunosuppression and improve outcomes after incomplete ablation by potentiating immunotherapy responsiveness.

Li Y, Liu K, Guo J et al. · Advanced healthcare materials · (2026) · View on PubMed ↗

Acute and chronic application of novel incremental breath-hold technique increases endurance exercise performance in healthy men and male military personnel.

This study tested acute and chronic effects of a novel incremental breath-hold technique (BHT) on endurance performance in healthy men and male military personnel. The key finding is that BHT acutely increased physiological markers such as V̇O2 and hemoglobin and altered end-tidal gas measures, and it improved endurance exercise performance in the tested settings. The significance is that a practical breath-hold protocol may enhance endurance capacity through pulmonary gas-exchange and oxygen-transport adaptations, with potential utility for athletic and military performance.

Burley MJ, Wall BT, Bond B et al. · Physiological reports · (2026) · View on PubMed ↗

Darolutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase 3 ARANOTE Trial.

This post hoc analysis of the phase 3 ARANOTE trial studied darolutamide plus androgen-deprivation therapy (ADT) versus placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer, stratified by CHAARTED high-volume and LATITUDE high-risk criteria. Darolutamide plus ADT significantly reduced radiologic progression or death across these disease volume/risk subgroups while maintaining favorable safety. These findings support darolutamide as an effective ADT intensification strategy for higher-burden metastatic hormone-sensitive prostate cancer populations.

Saad F, Shore N, Vjaters E et al. · European urology · (2026) · View on PubMed ↗

---

Breast cancer (TNBC, HER2 ADC, perioperative ctDNA, epigenetic therapy)

Spatial proteogenomic profiling uncovers sensitization strategies for antibody-drug conjugate in HER2-positive breast cancer.

This study used spatial proteogenomic profiling with imaging mass cytometry to investigate determinants of antibody-drug conjugate (ADC) response in 47 HER2-positive/hormone receptor-negative breast cancers treated with the HER2-targeting ADC SHR-A1811 in the FASCINATE-N trial. Elevated tumor-cell H3K27ac expression predicted improved ADC efficacy, while collagen-positive fibroblasts mediated resistance, and combining the ADC with chidamide (histone deacetylase inhibitor) or losartan (collagen-modulating agent) produced synergistic antitumor effects. The work provides spatial biomarkers and combination strategies to overcome microenvironment-driven resistance to HER2 ADC therapy.

Cai YW, Jia SH, Wang H et al. · Cell reports. Medicine · (2026) · View on PubMed ↗

Tissue-Free vs Tumor-Informed ctDNA Assays for Molecular Residual Disease Detection in Early Triple Negative Breast Cancer.

The study evaluated tissue-free circulating tumor DNA (ctDNA) assays for molecular residual disease (MRD) detection in early triple-negative breast cancer (TNBC) and compared performance with tumor-informed ctDNA assays. In moderate-to-high recurrence–risk TNBC patients, tissue-free ctDNA analysis was assessed for prognostic utility and concordance with tumor-informed results. If comparable accuracy is demonstrated, tissue-free MRD testing could simplify adjuvant decision-making workflows without requiring sequencing of the primary tumor.

Cunningham N, Cutts RJ, Swift C et al. · JAMA oncology · (2026) · View on PubMed ↗

First-line PD-1/VEGF bispecific antibody plus chemotherapy in triple-negative breast cancer: a phase 2 trial.

This phase 2 open-label, multicenter, single-arm trial studied first-line intravenous ivonescimab (PD-1/VEGF bispecific antibody) plus chemotherapy (paclitaxel or nab-paclitaxel) in female patients with locally advanced unresectable or metastatic triple-negative breast cancer (TNBC) without prior systemic therapy. The key reported finding was the trial’s evaluation of safety and efficacy of the regimen using ivonescimab 20 mg/kg every 2 weeks combined with paclitaxel 90 mg/m2 or nab-paclitaxel 100 mg/m2 on days 1, 8, and 15 of 28-day cycles. Clinically, it tests whether dual PD-1/VEGF blockade with standard chemotherapy can improve outcomes in a high-risk TNBC population that lacks effective targeted options.

Shao X, Tian C, Chen Z et al. · Nature medicine · (2026) · View on PubMed ↗

---

Lung cancer (NSCLC/SCLC, EGFR, PD-1 resistance, radiotherapy/bio-markers)

Symptoms and treatment response to florensocatib and inhaled tobramycin in bronchiectasis: Post hoc analysis of two randomized trials.

This post hoc analysis examined whether baseline symptom burden (measured by the Quality of Life-Bronchiectasis Respiratory Symptom Scale, QoL-B-RSS) predicts differential treatment response to florensocatib versus inhaled tobramycin in bronchiectasis using data from two multicentre randomized trials (SAVE-BE, n=224; TORNASOL, n=357). Florensocatib reduced exacerbation rates versus placebo, with similar relative risk reductions observed across higher and lower baseline symptom-burden strata. Clinically, this suggests that symptom burden may not meaningfully limit the benefit of florensocatib, helping clinicians anticipate response regardless of baseline QoL-B-RSS status.

Gao YH, Li XS, Sun XL et al. · Cell reports. Medicine · (2026) · View on PubMed ↗

SYS6010, epidermal growth factor receptor-targeting antibody-drug conjugate for advanced non-small cell lung cancer: A phase 1 trial.

A phase 1 trial studied SYS6010, an epidermal growth factor receptor (EGFR)-targeting antibody-drug conjugate, in 236 patients with advanced non-small cell lung cancer (NSCLC). The key findings included a dose-limiting toxicity at 6.4 mg/kg with subsequent cohort expansion doses (4.2, 4.5, 4.8 mg/kg), very high rates of treatment-related adverse events and an objective response rate of 34.7% in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors and platinum chemotherapy. These results support continued clinical development of SYS6010 as a targeted ADC option for EGFR-driven NSCLC with an emerging efficacy and tolerability profile.

Li ZM, Zhou Z, He ZY et al. · Cancer cell · (2026) · View on PubMed ↗

Somatic alterations in TP53, PIK3CA, and CCND1 reveal exposure-driven patterns in oral and oropharyngeal tumors.

This study analyzed somatic alterations in 1,086 oral cavity (OC) and oropharyngeal (OPC) tumors (606 OC, 480 OPC including 287 HPV-positive OPC) profiled with a 1,109-gene panel to determine how tobacco, alcohol, and HPV exposures shape tumor molecular landscapes, focusing on TP53, PIK3CA, and CCND1. HPV-positive OPC showed APOBEC-driven mutations and a subset with FGFR3 co-occurrence, whereas HPV-negative OPC and OC were characterized by 3q26/28 amplifications involving PIK3CA/TP63/SOX2 and TP53 was the most frequently mutated gene in HPV-negative tumors. These exposure-linked genomic patterns can improve mechanistic understanding and potentially refine molecular risk stratification for head and neck cancers by etiology.

Cortez Cardoso Penha R, Virani S, Holt JR et al. · Journal of the National Cancer Institute · (2026) · View on PubMed ↗

AQP4-IgG-positive myelitis occurring in a patient with small cell lung cancer: a case report.

This case report described a 65-year-old man with extensive-stage small cell lung cancer (SCLC) who developed acute urinary retention followed by rapidly progressive paraplegia, with spinal MRI showing longitudinally extensive intramedullary T2-hyperintense lesions. The clinical picture raised diagnostic uncertainty between metastatic spinal cord involvement and inflammatory myelitis, and the report focused on an AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD) diagnosis. The significance is that AQP4-IgG-positive NMOSD can mimic cancer-related spinal metastasis in SCLC, emphasizing the need for immunologic testing when imaging and clinical course suggest inflammatory myelitis.

Yang M, Du D, Cao X et al. · Frontiers in oncology · (2026) · View on PubMed ↗ · Free PDF ↗

Biomarkers of nivolumab benefit in resectable non-small cell lung cancer.

This study analyzed perioperative biomarker responses in resectable non-small cell lung cancer patients from the CheckMate 77T trial to identify circulating tumour DNA (ctDNA) patterns associated with benefit from nivolumab. Among evaluable patients, ctDNA was detectable at baseline and at neoadjuvant completion in most nivolumab-treated patients (83/98 at baseline; 90/98 at completion) and in most placebo-treated patients as well (75/92 at baseline; 78/92 at completion). The results support ctDNA as a clinically measurable biomarker framework for stratifying nivolumab benefit in the perioperative setting.

Cascone T, Awad MM, Spicer JD et al. · Nature · (2026) · View on PubMed ↗ · Free PDF ↗

PGE2-mediated NK cell reprogramming drives acquired immunotherapy resistance in lung adenocarcinoma.

This study examined mechanisms of acquired resistance to PD-1 blockade in lung adenocarcinoma, using an orthotopic bioluminescence-tracked Lewis lung carcinoma (LLC1) model in immunocompetent mice treated with anti–PD-1. Through an in vivo genome-wide CRISPR loss-of-function screen and validation with inducible tetracycline-off knockdown approaches, it identified a PGE2-driven NK cell reprogramming program that promotes relapse under immunotherapy pressure. The work links a tumor/immune mediator (PGE2) to NK cell functional remodeling as a driver of anti–PD-1 resistance, offering a potential pathway for combination strategies.

Wang Y, Peng C, Feng S et al. · Journal for immunotherapy of cancer · (2026) · View on PubMed ↗

---

Hematologic malignancies (MM, AML, lymphoma, CAR-T/BsAb, immunotherapy trials)

Sequenced, Not Stirred: Positioning CAR T and Bispecific Antibody Therapy in Multiple Myeloma.

This article reviewed real-world outcomes in more than 600 multiple myeloma patients treated with chimeric antigen receptor T-cell (CAR T) therapy and/or bispecific antibodies, emphasizing patients receiving both sequentially. Progression-free survival was better when CAR T was given first, and the advantage was attributed to CAR T’s upfront benefit because outcomes after progression were similar when the sequence was reversed. Clinically, the findings support sequencing CAR T before bispecific therapy when feasible to maximize early disease control.

Banerjee R · Blood cancer discovery · (2026) · View on PubMed ↗

Development and Validation of a Novel Geriatric Risk Score for Prognostication in Older Patients With Hodgkin Lymphoma: A Multicenter Retrospective Study.

This multicenter retrospective study developed and validated a geriatric risk score for older patients (≥60 years) with Hodgkin lymphoma (HL) across 14 centers in China from 2006–2024. The key finding was that a prognostic model integrating metabolic tumor burden with geriatric assessment improved risk stratification compared with commonly used tools such as the International Prognostic Score (IPS) and Comprehensive Geriatric Assessment (CGA). This provides a more discriminative, clinically usable approach to predict outcomes in older HL patients where frailty and disease biology jointly affect survival.

Zhao P, Wang Y, Bai M et al. · American journal of hematology · (2026) · View on PubMed ↗

Clinical outcomes associated with NPM1 mutations in newly diagnosed acute myeloid leukemia.

This retrospective analysis assessed clinical outcomes and survival predictors in 396 newly diagnosed NPM1-mutated acute myeloid leukemia (NPM1mt AML) patients treated at MD Anderson Cancer Center. The study found that treatment intensity (including high-intensity chemotherapy) and other covariates were associated with overall survival, with high-intensity chemotherapy yielding a median overall survival of 84.7 months and a 5-year OS rate of 53% (reported with confidence intervals). These data help refine prognostic expectations for NPM1mt AML and guide risk-adapted therapy selection in a molecularly defined AML subgroup.

Farhat A, El Hajjar G, Kantarjian H et al. · Cancer · (2026) · View on PubMed ↗

The Great Debate: CAR-T-Cell Therapy Versus Bispecific Antibodies in B-Cell Lymphoma.

This narrative synthesis compared CD19-directed CAR-T-cell therapy versus CD20×CD3 bispecific antibodies in relapsed/refractory large B-cell lymphoma using phase 2/3 trial data, real-world evidence, and meta-analyses. It found that in the second-line setting CAR-T therapy shows superior event-free survival and progression-related outcomes compared with bispecific antibodies, while acknowledging the lack of prospective head-to-head randomization. This helps clinicians and researchers interpret current evidence when selecting between CAR-T and BsAbs and highlights the need for randomized comparisons.

Martino M, Marafioti V, Pitea M et al. · Cancers · (2026) · View on PubMed ↗

Mechanistic and Clinical Differences Between Daratumumab and Isatuximab in Multiple Myeloma: Emerging Roles of 1q Gain and Immune Remodeling.

This review studied mechanistic and clinical differences between the anti-CD38 monoclonal antibodies daratumumab and isatuximab in multiple myeloma, emphasizing how immune remodeling and genomic features such as 1q gain may influence response. It found that despite targeting CD38, the antibodies differ in epitope recognition and downstream biology, including isatuximab’s near-catalytic-site binding leading to enzymatic inhibition, enhanced internalization, FOXM1 suppression, and reactive oxygen species-mediated cytotoxicity. This supports more tailored treatment selection in MM based on mechanistic fit and patient-specific factors like 1q gain and immune context.

Kikuchi J, Yasui H · Cells · (2026) · View on PubMed ↗

TIM3-targeted delivery of venetoclax overcomes drug resistance and reinvigorates NK cell activity in acute myeloid leukemia.

This preclinical study investigated TIM3-targeted delivery of venetoclax using a nanoformulated platform called VINCENT (VEN-integrated natural killer cell engager targeting TIM3) in acute myeloid leukemia (AML). It found that VINCENT overcomes venetoclax resistance in VEN-resistant AML cell lines and patient-derived xenografts by improving VEN delivery, eliminating TIM3+ blasts and dysfunctional T cells, and reactivating NK cells. This supports a translational strategy combining anti-TIM3/anti-CD16 targeting with venetoclax to treat resistant AML, including in older or unfit patients.

Wang Q, Li J, Zeng X et al. · Nature cancer · (2026) · View on PubMed ↗

An inherent T cell-activating mRNA delivery carrier for in vivo CAR T generation.

The study developed an inherent T cell-activating polymer–lipid nanoparticle carrier (ERTLNPs) for in vivo delivery of CAR T–generating mRNA in vivo. It found that ligand-free ERTLNPs using p-toluenesulfonyl arginine (RT)-modified oligoethylenimine-based lipid nanoparticles preferentially transfected T cells in the spleen and activated them to enable in vivo CAR T generation. This provides a scalable, non-invasive mRNA-based approach to CAR T manufacturing that avoids antibody-conjugated lipid nanoparticles and improves in vivo transfection efficiency.

Cao Q, Yao Y, Zheng W et al. · Nature materials · (2026) · View on PubMed ↗

Mefatinib versus gefitinib as a first-line treatment for EGFR-mutated non-small cell lung cancer: a randomized, double-blind, multicenter phase III study.

This phase III randomized, double-blind, multicenter trial compared the EGFR tyrosine kinase inhibitors mefatinib versus gefitinib as first-line therapy in Chinese patients with advanced nonsquamous NSCLC harboring EGFR L858R or exon 19 deletion (ex19del). The key finding was the trial’s efficacy assessment with progression-free survival (PFS) as the primary endpoint, comparing mefatinib 60 mg daily (n=223) against gefitinib 250 mg daily (n=113) as determined by an independent review committee. Clinically, it tests whether mefatinib improves outcomes over standard first-generation EGFR inhibition in a genetically defined NSCLC population.

Yu J, Xiong A, Wang Q et al. · Signal transduction and targeted therapy · (2026) · View on PubMed ↗ · Free PDF ↗

Treatment Modalities and the Impact of Granulocyte Colony-Stimulating Factor in AML Patients Treated With Venetoclax and Azacitidine: A DATAML Registry Study.

This DATAML registry study analyzed real-world treatment patterns and outcomes in older or chemotherapy-ineligible AML patients treated with azacitidine plus venetoclax (AZA-VEN), focusing on the impact of granulocyte colony-stimulating factor (G-CSF). It included 199 patients and reported baseline characteristics and outcomes in relation to G-CSF use, aiming to explain differences from the registration trial’s overall survival results. Clinically, it informs how supportive care with G-CSF may affect tolerability, response, and survival in AZA-VEN-treated AML patients.

Lapierre L, Laemmel L, Bérard E et al. · Clinical lymphoma, myeloma & leukemia · (2026) · View on PubMed ↗

SOHO State of the Art Updates and Next Questions | Predictive Markers for Ruxolitinib in Myelofibrosis.

This article is a state-of-the-art review summarizing predictive biomarkers for ruxolitinib response in myelofibrosis (MF), a JAK-STAT–driven myeloproliferative neoplasm. It highlights that while ruxolitinib (a JAK1/JAK2 inhibitor) is standard for intermediate- and high-risk MF, response variability and early discontinuation/progression create a need for reliable predictors. The scientific significance is consolidating current evidence on candidate biomarkers to improve patient selection and optimize ruxolitinib-based management in MF.

Palandri F, Branzanti F · Clinical lymphoma, myeloma & leukemia · (2026) · View on PubMed ↗

---

Immunotherapy mechanisms & tumor microenvironment (CAR-T barriers, PD-1 resistance, immune biomarkers)

In vivo genome-wide CRISPR screens of human T cells in solid tumours.

The study performed in vivo genome-wide CRISPR knockout screens in human T cells recovered from solid-tumour-bearing mice to identify genetic regulators of T cell performance in the tumour microenvironment. The authors developed an efficient tumour-to-T-cell recovery model enabling genome-wide CRISPR screening with few mice and found tumour-infiltrating T cells show dysfunction hallmarks compared with splenic T cells, providing a physiologically relevant screening context. This work enables scalable discovery of immunotherapy-relevant gene targets that may not be revealed by in vitro T cell assays.

Liu Q, Chen PA, Urs E et al. · Nature · (2026) · View on PubMed ↗

N-glycans in non-malignant tumor microenvironment cells dampen CAR-T cell function in solid tumors.

This study investigated how N-glycans expressed by non-malignant tumor microenvironment cells impair chimeric antigen receptor (CAR) T-cell function in solid tumors, focusing on M2-like macrophages and hepatic stellate cells in liver metastases from colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC). Using in vitro co-culture systems, transcriptomic analysis, and tumor-bearing humanized mouse models, the authors found that N-glycans in these non-malignant populations dampen CAR-T activity. These results identify tumor microenvironment N-glycans as a mechanistic barrier to CAR-T efficacy in solid tumors and suggest potential targets to improve responses.

Sirini C, Balestrieri C, Greco B et al. · Journal for immunotherapy of cancer · (2026) · View on PubMed ↗ · Free PDF ↗

---

Autoimmune disease & inflammation (SLE/LN, RA, atopic dermatitis, vitiligo, axSpA)

Low-dose blinatumomab in multidrug-resistant rheumatoid arthritis-a case series.

This named-patient case series evaluated low-dose blinatumomab, a T-cell engager, in 15 patients with multidrug-resistant rheumatoid arthritis (MDR-RA) and monitored safety and efficacy. The key finding was that low-dose blinatumomab was feasible with attention to cytokine release syndrome (CRS) and immune effector cell-related neurotoxicity syndrome (ICANS), alongside improvements in clinical disease activity measures and tissue inflammation assessed by ultrasound. The results support further study of lower-dose blinatumomab protocols as a potentially safer immunotherapy strategy in refractory autoimmune disease.

Bucci L, Hagen M, Böltz S et al. · Annals of the rheumatic diseases · (2026) · View on PubMed ↗

Spatially distinct macrophage subsets drive myofibroblast heterogeneity and maladaptive fibrosis in lupus nephritis.

This study investigated how spatially distinct macrophage subsets interact with fibroblast populations to drive myofibroblast heterogeneity and maladaptive fibrosis in lupus nephritis (LN) using single-cell RNA sequencing and spatial transcriptomics. In 156 human LN biopsies and 30 healthy controls (Accelerating Medicines Partnership–SLE cohort) and corresponding mouse models, the authors identified distinct macrophage–fibroblast interaction patterns that map to profibrotic myofibroblast states. These findings clarify immune–stromal crosstalk mechanisms in LN and suggest macrophage subset targeting as a therapeutic opportunity to limit renal fibrosis.

Raparia C, Hoover P, Ai J et al. · Annals of the rheumatic diseases · (2026) · View on PubMed ↗

Efficacy and safety of upadacitinib in adults and adolescents for treatment of non-segmental vitiligo (Viti-Up): results of two phase 3 randomised controlled studies.

Viti-Up studied the efficacy and safety of upadacitinib, a selective once-daily Janus kinase (JAK) inhibitor, in adults and adolescents (≥12 years) with non-segmental vitiligo across two phase 3, global, multicentre, randomized, double-blind, placebo-controlled trials. The key finding was the therapeutic benefit of systemic upadacitinib for non-segmental vitiligo with a defined safety profile in this population. This supports JAK inhibition as a systemic treatment option for vitiligo where no systemic therapies were previously approved.

Passeron T, Prajapati VH, Sivamani RK et al. · Lancet (London, England) · (2026) · View on PubMed ↗

GPR84 and Neuroinflammation: A Receptor Worth Targeting, or A Target Worth Reconsidering?

This article reviewed evidence on the medium-chain fatty acid–sensing receptor GPR84 and its role in neuroinflammation across innate immune cells and microglia. It concluded that GPR84 activation can amplify pro-inflammatory signaling (including MAPK/ERK, NF-κB, and NLRP3 inflammasome pathways) and is linked to disease-associated microglial states, while also noting context-dependent protective roles that complicate target validation. The significance is that GPR84 remains a candidate target but requires careful reconsideration of disease context and therapeutic window.

Jarco J, Malek N · Molecular neurobiology · (2026) · View on PubMed ↗

Corticosteroids in ARDS: old controversies, new insights, and future directions.

This narrative review analyzed the role of corticosteroids in acute respiratory distress syndrome (ARDS), focusing on controversies and emerging insights. It emphasized that glucocorticoid receptor signaling (genomic and non-genomic) interacts with timing, inflammatory burden, and host response, and that clinical trials support corticosteroids in moderate-to-severe ARDS—especially COVID-19 ARDS and severe community-acquired pneumonia—though effects vary by etiology and biological subphenotype. The review’s significance is guiding future precision approaches using ARDS subtyping to identify patients most likely to benefit from corticosteroids.

Daoud T, Villar J, Annane D · Intensive care medicine · (2026) · View on PubMed ↗

Real-world Effectiveness and Safety of Lebrikizumab in Atopic Dermatitis: A TREATgermany Analysis.

This TREATgermany real-world analysis evaluated adult patients with moderate-to-severe atopic dermatitis treated with the IL-13 inhibitor lebrikizumab, assessing effectiveness and safety at 1, 3, and 6 months in 108 initiators (80 with follow-up) including 41 switchers without a washout from another advanced systemic therapy. The study found treatment responses and tolerability in routine care across both treatment-naïve and switcher groups over the first 6 months. These data extend clinical trial evidence by characterizing real-world effectiveness and safety for lebrikizumab in a heterogeneous adult AD population.

Kind B, Pham C, Heinrich L et al. · Acta dermato-venereologica · (2026) · View on PubMed ↗

The role of glucagon-like peptide 1 receptor agonists in the management of patients with inflammatory bowel diseases.

This review examined the role of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in managing patients with inflammatory bowel diseases (Crohn’s disease and ulcerative colitis), motivated by the high prevalence of overweight/obesity and visceral adipose tissue (VAT) that worsen IBD outcomes. It synthesizes evidence linking obesity/VAT to increased disease activity, reduced therapeutic response, and higher surgical and postoperative recurrence risk, and discusses how GLP-1 RAs may address cardiometabolic comorbidities relevant to IBD. Scientifically and clinically, the article frames GLP-1 RA use as a potential strategy to mitigate obesity-associated drivers of adverse IBD outcomes and related metabolic disease.

Beniwal-Patel P, Samaan S, Abreu MT et al. · Inflammatory bowel diseases · (2026) · View on PubMed ↗

Lactate and lactylation in sepsis: regulation of immune-metabolic crosstalk and organ injury.

This Frontiers in Immunology review examined how lactate and lysine lactylation (Kla) regulate immune-metabolic crosstalk and organ injury in sepsis. It synthesizes evidence that hyperlactatemia is not only a prognostic biomarker but also a pathogenic epigenetic modulator via Kla, driven by sepsis-induced Warburg-like glycolytic reprogramming in immune and parenchymal cells. The review highlights Kla as a mechanistic bridge between metabolism and inflammation that could inform new therapeutic targets in sepsis.

Li Z, Gu WJ, Li T et al. · Frontiers in immunology · (2026) · View on PubMed ↗ · Free PDF ↗

The Metabolic Revolution in Dermatology: Obesity, Insulin Resistance, and Ultra-Processed Diets as Drivers of Skin Inflammation.

This narrative review examined how obesity, insulin resistance, and ultra-processed diets influence skin inflammation through systemic metabolic and endocrine mechanisms, focusing on adipokines/cytokines and Th1/Th17 skewing. It concludes that hyperinsulinemia and increased insulin-like growth factor-1 drive keratinocyte proliferation, sebum production, and autoinflammatory signaling that contribute to multiple inflammatory dermatoses. Clinically, the synthesis supports targeting metabolic drivers (e.g., insulin/IGF-1 axis and diet-related inflammation) as a strategy to improve outcomes across conditions such as hidradenitis suppurativa, acne, psoriasis, and atopic dermatitis.

Khalaf R, Chow W, Lazarowitz R et al. · Journal of cutaneous medicine and surgery · (2026) · View on PubMed ↗

Recent advances in the medical management of thyroid eye disease.

This review summarized recent advances in medical management of thyroid eye disease (TED), emphasizing targeted therapies beyond conventional treatment. It reports that intravenous methylprednisolone remains first-line for active moderate-to-severe TED but has limited efficacy for proptosis and diplopia, and it highlights emerging targeted options such as teprotumumab (as discussed in the review). The clinical significance is that newer targeted biologic approaches may better address key disfiguring and functional manifestations of TED compared with steroids alone.

Agarwal K, Rao-Waronski V, Thomas N et al. · Current opinion in endocrinology, diabetes, and obesity · (2026) · View on PubMed ↗

Clinical Effect of Bacterial Suspension in Patients with Moderate-to-Severe Allergic Conjunctivitis.

This before-and-after open, non-controlled clinical study investigated bacterial suspension as complementary immunomodulatory therapy in five children with moderate-to-severe allergic conjunctivitis. It found clinically relevant improvements in ocular symptoms and quality-of-life measures after treatment with the bacterial suspension, compared with baseline. This suggests a potential adjunct role for bacterial suspension in pediatric allergic conjunctivitis, warranting controlled trials to confirm efficacy and safety.

Casanova-Méndez I, Quintana-Mexiac GA, Alcalá-Gallegos JL et al. · Journal of clinical medicine · (2026) · View on PubMed ↗

Epigenetic modulation of stromal cell states underpins pathological tissue niches in Crohn’s disease.

The study mapped stromal cell states in human Crohn’s disease using single-cell spatial transcriptomics, RNA sequencing, and ATAC sequencing of ~2.5 million cells from full-thickness bowel tissue. It found that inflammatory fibroblasts are induced by combinatorial cytokine exposure, stabilized by transcription factor activity (including GLI3, TWIST1, ETV4, PRDM1, and RELB), and do not spontaneously revert, with epigenetic modulation underpinning pathological niche formation. This identifies specific stromal regulatory programs and epigenetic control points that could be targeted to disrupt disease-promoting tissue niches in Crohn’s disease.

Koplev S, Sharma O, Woelfel S et al. · Nature immunology · (2026) · View on PubMed ↗

Efficacy and safety of filgotinib in patients with active radiographic and nonradiographic axial spondyloarthritis: results from OLINGUITO, a phase 3 trial consisting of 2 randomised, placebo-controlled, double-blind, parallel-group studies.

This phase 3 OLINGUITO program studied filgotinib, a JAK1 preferential inhibitor, in patients with active radiographic or nonradiographic axial spondyloarthritis (axSpA) who had inadequate response or intolerance to at least two NSAIDs. Patients were randomized 1:1 to filgotinib 200 mg once daily or placebo through week 16 in two parallel double-blind placebo-controlled studies stratified by hs-CRP and prior bDMARD use. The significance is that it evaluates whether JAK1 inhibition improves clinical outcomes and safety across both r-axSpA and nr-axSpA subtypes in a broad international axSpA population.

Baraliakos X, Maksymowych WP, Navarro-Compán V et al. · Annals of the rheumatic diseases · (2027) · View on PubMed ↗ · Free PDF ↗

The lupus damage index revision program: Results from the item generation and reduction phases.

This study developed and refined a revised Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SLICC/ACR SDI) using literature review and Delphi consensus among international systemic lupus erythematosus experts and patients. Items were generated from evidence synthesis and then reduced by Delphi rounds, excluding SDI items with median appropriateness scores ≤4/9. The revised SDI framework aims to improve the validity and usability of damage measurement in systemic lupus erythematosus for future clinical research and practice.

Kundakci B, Barber MRW, Clarke AE et al. · Lupus science & medicine · (2026) · View on PubMed ↗ · Free PDF ↗

---

Kidney disease (IgA nephropathy, hypertension-related injury)

A cross-organ single-cell analysis of hypertension.

The study performed cross-organ single-cell analysis of hypertension-induced end-organ damage in angiotensin II-treated mice, Dahl salt-sensitive rats, and spontaneously hypertensive rats. It identified conserved and model-specific gene programs across vascular smooth muscle and renal tubular compartments, and integration with human genomic data prioritized a noncoding variant (rs28451064) linked to blood pressure and renal injury traits (as indicated by the truncated abstract). This work provides a cell-type-resolved map of hypertension biology that can connect animal models to human genetic risk.

Qiu Q, Liu Y, Xue H et al. · Science (New York, N.Y.) · (2026) · View on PubMed ↗

Efficacy and safety of BAFF/APRIL-pathway inhibitors versus placebo in adults with IgA nephropathy: a systematic review with pairwise and network meta-analysis.

This systematic review with pairwise and network meta-analysis studied BAFF/APRIL-pathway inhibitors versus placebo in adults with biopsy-proven IgA nephropathy (IgAN). It found comparative efficacy signals for reducing proteinuria and improving estimated glomerular filtration rate (eGFR) across BAFF/APRIL inhibitors, while synthesizing safety and effect sizes across randomized placebo-controlled trials. This helps rank BAFF/APRIL-targeted therapies for IgAN and supports evidence-based selection pending direct head-to-head trials.

Mansour N, Elbarody RMF, Kamel AM · BMC nephrology · (2026) · View on PubMed ↗

---

Cardiovascular disease & metabolism (heart failure CRT pacing, Lp(a), coronary risk, exercise/proteomics)

Immunological risk identified by single-cell multi-omics and cardiovascular outcomes.

This exploratory nested case-control study within the LURIC cohort (n=3316) used single-cell multi-omics to identify immunological signals in 44 individuals with and without angiographically confirmed coronary artery disease (CA) and related these signals to cardiovascular risk beyond hsCRP and IL-6. The study identified immunological risk signatures enriched in patients with higher cardiovascular risk, implicating specific immune-cell programs as determinants not captured by conventional inflammatory biomarkers. These findings support single-cell multi-omics as a route to discover clinically actionable immune biomarkers for CA risk stratification in humans.

Horstmann H, Anto Michel N, Losert C et al. · European heart journal · (2026) · View on PubMed ↗

TREM2 signaling in cardiovascular disease: macrophage heterogeneity, timing, and therapeutic opportunity.

This Journal of Advanced Research review summarized evidence on TREM2 signaling in cardiovascular disease, emphasizing macrophage heterogeneity and spatiotemporal dynamics across conditions. The key finding is that TREM2 acts as a pivotal molecular hub shaping the functional duality of TREM2+ macrophages in diseases including atherosclerosis, myocardial infarction, heart failure, and sepsis-induced cardiogenic shock. The review highlights timing- and context-dependent therapeutic opportunities for targeting TREM2+ macrophage programs to modulate maladaptive immune-metabolic crosstalk in cardiovascular pathology.

Yang K, Ma X, Wang B et al. · Journal of advanced research · (2026) · View on PubMed ↗

Once-weekly IcoSema versus once-daily insulin glargine U100 in type 2 diabetes management (COMBINE 4): an open-label, multicentre, treat-to-target, randomised, phase 3b trial.

COMBINE 4 studied once-weekly IcoSema (a fixed combination of basal insulin icodec plus the GLP-1 receptor agonist semaglutide) versus once-daily insulin glargine U100 in adults with type 2 diabetes inadequately controlled on oral glucose-lowering medications. In this 40-week, open-label, treat-to-target phase 3b randomized trial, IcoSema was evaluated for comparative efficacy and safety as an insulin intensification strategy combining GLP-1RA and basal insulin. If effective with acceptable hypoglycaemia and weight outcomes, this regimen could provide a guideline-concordant, lower-burden (weekly) alternative to basal insulin alone for stepwise type 2 diabetes management.

Ji L, Benamar M, Mohan V et al. · The lancet. Diabetes & endocrinology · (2026) · View on PubMed ↗

Exercise intensity modulates interorgan communication and is associated with cardiometabolic health outcomes in humans.

A multi-cohort human exercise intervention studied how sprint-interval exercise (SIE) versus moderate-intensity exercise (MIE) modulates interorgan communication and relates to cardiometabolic health outcomes in untrained and trained participants. Exercise intensity distinctly altered the plasma proteome and metabolome, and the study integrated multi-organ gene and protein expression to link these molecular changes to health outcomes. These findings identify intensity-dependent circulating signals that may help explain why different exercise prescriptions produce different cardiometabolic effects.

Olsen L, Botella J, Barrows D et al. · Cell reports. Medicine · (2026) · View on PubMed ↗

Insulin resistance is associated with mammary mitochondrial dysfunction at the onset of human lactation.

The study investigated mechanisms linking insulin resistance to delayed secretory activation (SA) by profiling mammary transcriptomes and insulin resistance–related hormones in 75 breastfeeding women during postpartum days 1–5. Women in the highest insulin resistance tertile (based on plasma leptin-to-adiponectin ratio) showed later SA onset and greater neonatal weight loss, associated with mammary mitochondrial dysfunction at the onset of human lactation. These human data connect insulin resistance to impaired mammary energy biology, offering mechanistic targets to improve lactation outcomes.

Meng X, Elajnaf T, Rostom H et al. · The Journal of clinical investigation · (2026) · View on PubMed ↗

Novel Lipoprotein (a) Therapies: A Comprehensive Review.

This comprehensive review summarized the current pipeline of lipoprotein(a) [Lp(a)]-lowering therapies, emphasizing RNA-based approaches designed to specifically reduce genetically determined Lp(a) levels. It synthesized evidence from phase 1–3 trials, regulatory updates, and ongoing cardiovascular outcomes trials (CVOTs) through mid-2026. The review highlights mechanistic and clinical progress toward therapies that address a major residual cardiovascular risk factor not well controlled by statins or PCSK9 inhibitors.

Ebubechukwu U, Ugoala O, Shahid R et al. · Current atherosclerosis reports · (2026) · View on PubMed ↗

Role of Hypoxia-Inducible Factor-1α in Regulating Muscle Degeneration After Rotator Cuff Tears.

This controlled laboratory study investigated the role of hypoxia-inducible factor-1α (HIF-1α) in muscle degeneration after rotator cuff tears using a murine model with supraspinatus tendon transection and suprascapular nerve transection (TTDN). The key finding is that HIF-1α regulates processes linked to stem cell differentiation and subsequent muscle degeneration following the injury-induced hypoxic stress environment. Scientifically, it identifies HIF-1α as a mechanistic driver of post-injury muscle deterioration, suggesting a potential therapeutic target to mitigate degeneration after rotator cuff tears.

Zhang H, Lee A, Liu M et al. · The American journal of sports medicine · (2026) · View on PubMed ↗

Anti-Obesity Medications in Longevity and Aesthetic Medicine.

This narrative review studied anti-obesity medications—specifically GLP-1 receptor agonists (semaglutide, liraglutide) and the dual GIP/GLP-1 agonist (tirzepatide)—in relation to longevity and aesthetic medicine. It found that these drugs produce substantial weight loss and emerging benefits beyond adiposity, with mechanistic and trial evidence suggesting possible links to ageing biology and appearance-related outcomes. This supports further clinical and mechanistic research to determine whether GLP-1/GIP-based therapies meaningfully modify ageing pathways and healthspan.

Bijoch J · Journal of clinical medicine · (2026) · View on PubMed ↗ · Free PDF ↗

Dietary Interventions and Testosterone Levels in Obese Men: A Systematic Review Comparing the Mediterranean Diet, Ketogenic Diet, and Intermittent Fasting.

This systematic review studied dietary interventions—Mediterranean diet, ketogenic diet, and intermittent fasting—in obese men with male obesity secondary hypogonadism, focusing on testosterone restoration. It found that the included human studies reported differential effects on testosterone levels depending on diet pattern, with evidence quality and magnitude varying across interventions. This informs non-pharmacologic management strategies for obesity-related low testosterone and identifies where better comparative trials are needed.

La Vignera S, Condorelli RA · Nutrients · (2026) · View on PubMed ↗

Meloxicam protects against muscle and metabolic decline in ageing through Cdon restoration and oxidative stress modulation.

This work investigated how the cell adhesion molecule Cdon regulates adult muscle maintenance during aging and tested whether meloxicam (Mcam) can counter muscle and metabolic decline in aging models. It found that Cdon expression declines with human aging, sarcopenia, and muscle-wasting disease, and that meloxicam protects against muscle and metabolic deterioration by restoring Cdon and modulating oxidative stress. These findings suggest a mechanistic, drug-repurposing strategy to target upstream regulators of sarcopenia via Cdon/oxidative-stress pathways.

Bae JH, So HK, Jeong Y et al. · Experimental & molecular medicine · (2026) · View on PubMed ↗

Conduction system vs. biventricular pacing in heart failure with reduced ejection fraction: a meta-analysis of randomized controlled trials.

This meta-analysis of randomized controlled trials compared conduction system pacing (CSP) versus biventricular pacing (BiVP) in patients with heart failure with reduced ejection fraction (HFrEF) undergoing cardiac resynchronization therapy (CRT). Across 13 RCTs (1320 participants; 657 CSP, 663 BiVP), CSP was associated with a lower risk of the composite outcome reported in the analysis compared with BiVP. If confirmed in full outcome reporting, CSP could represent a more physiologic CRT alternative with improved clinical effectiveness in HFrEF.

Karakasis P, Vlachos K, Siontis KC et al. · Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · (2026) · View on PubMed ↗

---

Neurodegeneration & neurobiology (tau/TDP-43, mitochondria, synapses/engram, glia, AD/ALS genetics)

The UNC13A cryptic exon associates with cognitive impairment in Alzheimer’s disease.

This genetic association study examined whether a UNC13A cryptic exon–tagging SNP (rs12973192 C>G) linked to impaired TDP-43–dependent splicing is associated with cognitive impairment in Alzheimer’s disease (AD). The key finding was that the UNC13A cryptic exon variant correlated with worse cognitive outcomes in AD, consistent with disrupted RNA splicing regulation by TDP-43. This suggests UNC13A cryptic exon biology as a potential modifier of AD cognitive decline and a mechanistic bridge between TDP-43 splicing dysfunction and neurodegeneration.

Reeves MM, Aviles Carpintero S, Zanovello M et al. · Alzheimer’s research & therapy · (2026) · View on PubMed ↗

Associations of self-reported and objectively measured physical activity and amyotrophic lateral sclerosis risk.

This UK Biobank analysis used Cox regression with cubic splines to test associations between self-reported and device-measured physical activity and incident amyotrophic lateral sclerosis (ALS), including stratification by genetic risk. The key finding was that physical activity showed an association with ALS risk, and the relationship differed when restricting analyses to participants with increased genetic risk due to C9ORF72 expansion carriage or UNC13A rs12608932 C-allele homozygosity. Scientifically, it supports a gene–environment interaction model for ALS risk and informs how lifestyle factors may differentially affect genetically susceptible individuals.

Gao J, Chalitsios CV, Bennett D et al. · Journal of neurology, neurosurgery, and psychiatry · (2026) · View on PubMed ↗

Decoding TREM2: A microglial receptor governing the fate of myelin.

This Cellular Signalling review focused on TREM2, a microglial receptor, and synthesized evidence for how TREM2 governs microglial fate decisions that influence myelin integrity and regeneration across CNS diseases. The key takeaway is that TREM2 is expressed not only by resident microglia but also by border-associated macrophages and lesion-infiltrating monocyte-derived macrophages, where it regulates lipid transport, lysosomal degradation, immune balance, and polarization. This positions TREM2 signaling as a mechanistic target for therapies aimed at improving myelin repair in disorders such as MS and AD.

Zhang Z, Zhang W, Jin L et al. · Cellular signalling · (2026) · View on PubMed ↗

Tau can wreak havoc in brain cells’ energy factories.

The report summarizes research showing that tau pathology disrupts mitochondrial function (“brain cells’ energy factories”) relevant to neurodegenerative disease. The key finding is that mitochondrial dysfunction is implicated as a driver of tau-associated cellular harm and suggests a potential therapeutic strategy targeting energy/mitochondrial pathways. This is significant because it points to actionable metabolic targets for Alzheimer’s disease and related tauopathies.

Reardon S · Science (New York, N.Y.) · (2026) · View on PubMed ↗

Artificial hibernation reveals synaptic engram architecture associated with memory retention.

The study used a mouse model of artificial hibernation to test how synaptic structural changes relate to memory retention, focusing on hippocampal synapses and dendritic spines. Despite extensive elimination of dendritic spines and synapses during hibernation, memory and hippocampal neuronal representations remained intact, and the authors identified a subset of spines associated with synaptic engram architecture (truncated). This suggests that stable memory traces may be maintained by specific synaptic subpopulations rather than by overall spine size or synapse abundance.

Lin YJ, Takahashi-Nakazato A, Tsutsumi K et al. · Science (New York, N.Y.) · (2026) · View on PubMed ↗

Selective Brain-Penetrant TTBK1 Inhibitors Modulate TDP-43 Pathology and Rescue Cognitive Deficits in a Mouse Model of TDP-43 Proteinopathy.

The study used a structure-guided medicinal chemistry program to discover selective, brain-penetrant TTBK1 inhibitors and tested their effects on TDP-43 pathology and cognition in a mouse model of TDP-43 proteinopathy. Lead compounds potently and selectively inhibited TTBK1 without impacting ciliogenesis and improved central nervous system outcomes, including modulation of TDP-43 pathology and rescue of cognitive deficits. This supports TTBK1 as a therapeutically actionable target for TDP-43–driven neurodegeneration while addressing TTBK2-related safety concerns.

Sanchez-Santos C, Jimenez-Amor A, Martinez-Gonzalez L et al. · Journal of medicinal chemistry · (2026) · View on PubMed ↗

A Multidimensional Engineering Strategy Reprograms Microglia via Targeted and Sustained-Release Extracellular Vesicles for Spinal Cord Injury Repair.

The study developed a multidimensional engineering approach using tetramethylpyrazine (TMP)-pretreated extracellular vesicles (TEVs) with targeted, sustained-release properties to reprogram microglia and promote spinal cord injury (SCI) repair. Engineered TEVs delivered anti-inflammatory and pro-regenerative cargo, improved targeting and controlled release kinetics, and thereby shifted microglia toward a reparative phenotype to enhance functional recovery after SCI. This provides a translational EV platform strategy to overcome key barriers in EV therapy for neuroinflammation-driven injury.

Xiong W, Liu M, Zheng M et al. · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · (2026) · View on PubMed ↗

Parkinson’s disease-associated PINK1 loss disrupts ensheathing glia and causes dopaminergic neuron synapse loss.

This study used unbiased single-cell sequencing of the entire brain in Drosophila Pink1 models to investigate how Parkinson’s disease-associated PINK1 loss affects ensheathing glia (EG), a cell type functionally similar to oligodendrocytes. Loss of Pink1 caused EG abnormalities resembling reactive responses to nerve injury and led to dopaminergic neuron synapse loss. The findings implicate glial dysfunction as an early, causal contributor to synaptic degeneration in Parkinson’s disease models, highlighting PINK1-dependent glia-neuron mechanisms.

Ghezzi L, Kuenen S, Pech U et al. · eLife · (2026) · 1 citations · View on PubMed ↗ · Free PDF ↗

Proteomic signatures of protected APOE ε4 carriers reveal causal pathways associated with delayed Alzheimer’s disease onset.

This study analyzed harmonized Global Neurodegeneration Proteomics Consortium (GNPC) plasma proteomics to identify causal pathways associated with delayed Alzheimer’s disease onset in “protected” APOE ε4 carriers versus ε4 carriers with AD. In 456 protected ε4 carriers (ε3/ε4 ≥75 years or ε4/ε4 ≥65 years with CDR=0) compared with 1,096 ε4 carriers with AD, proteomic models adjusted for age, sex, ε4 dosage, and proteomic principal components identified top protein signals linked to delayed onset. These proteomic signatures may reveal mechanisms underlying resilience in APOE ε4 carriers and support biomarker-driven pathway discovery for AD prevention.

Le Guen Y, Park J, Peña-Tauber A et al. · Alzheimer’s & dementia : the journal of the Alzheimer’s Association · (2026) · View on PubMed ↗

Procognitive restoration of PV neuron plasticity in neurodevelopmental disorders.

The study investigated how restoring parvalbumin (PV) neuron plasticity in the dentate gyrus–CA3/CA2 hippocampal circuit can improve memory-related function in neurodevelopmental disorder models. The authors report that procognitive restoration of PV neuron plasticity rescues experience-dependent control of pyramidal neuron activity, counteracting early-life PV impairments linked to network hyperexcitability and seizures. This provides a mechanistic therapeutic direction targeting PV interneuron plasticity to ameliorate cognitive and circuit dysfunction in neurodevelopmental disorders.

Shih YT, Alipio JB, Klaft ZJ et al. · Nature · (2026) · View on PubMed ↗

---

Genome engineering & molecular therapeutics (base/prime editing, nucleic acid design, CRBN degraders)

Genome-wide CRISPR screening identifies cellular factors controlling nonviral genome editing efficiency.

This genome-wide CRISPR screening study in human cells linked perturbation of 19,114 genes to nonviral genome editing efficiency outcomes across diverse payloads, loci, and cell types. It identified six negative regulators of delivery whose depletion increased base-editing efficiency up to six-fold, and validated GJB2 and BET1L in models correcting a pathogenic adenine base mutation in KCNJ13 and introducing a cytosine base mutation in the GABAA receptor gene. These results provide actionable host-factor targets to improve nonviral genome editing performance for therapeutic genome engineering.

Saxena S, Kabra M, Abdeen AA et al. · Nature communications · (2026) · View on PubMed ↗

Codon optimization depletes stop codons in alternative reading frames of protein-coding nucleic acid therapeutics.

This study investigated how codon optimization affects translation termination by depleting stop codons in alternative reading frames of protein-coding nucleic acid therapeutics, using quantitative dual-fluorescence reporters. It showed that stop codons in alternative frames act as molecular checkpoints that terminate out-of-frame translation, and genome-wide analyses across 10 organisms indicated natural coding sequences maintain dense stop codon distributions in alternative frames. The clinical/scientific significance is that codon optimization strategies for nucleic acid therapeutics may inadvertently increase out-of-frame translation risk by reducing these termination checkpoints, informing safer therapeutic design.

Liu Z, Ying Z, Shen L et al. · Proceedings of the National Academy of Sciences of the United States of America · (2026) · View on PubMed ↗

A regulatory adaptor for RAD51’s AAA+ unfoldase promotes homologous recombination-mediated DNA repair and genome stability.

The study investigated how MACIR/C5orf30 regulates the FIGNL1–FIRRM (C1orf112) AAA+ ATPase unfoldase to control RAD51 disassembly during homologous recombination (HR) in the setting of DNA double-strand breaks. MACIR was identified as an adaptor that binds FIRRM to promote RAD51 disassembly, thereby enhancing HR-mediated DNA repair and genome stability. These findings define a new HR regulatory axis (MACIR–FIRRM–FIGNL1) that could inform strategies to modulate genome maintenance and recombination fidelity.

Zhou T, Pang M, Liang X et al. · Proceedings of the National Academy of Sciences of the United States of America · (2026) · View on PubMed ↗

Nucleoside-Modified mRNA Encoding Alpha-Galactosidase A Ameliorates Fabry Disease Phenotypes in Human IPSC-Derived Cardiomyocytes.

This preclinical study tested nucleoside-modified mRNA encoding alpha-galactosidase A (modGLA mRNA) delivered to human induced pluripotent stem cell (iPSC)-derived cardiomyocytes to model Fabry disease. The treatment ameliorated Fabry disease phenotypes associated with α-galactosidase A deficiency and glycosphingolipid (Gb3) accumulation, building on prior preclinical evidence that systemic modGLA delivery improves glycosphingolipid reduction in the heart. Scientifically, it supports nucleoside-modified mRNA as a potential therapeutic platform for lysosomal enzyme replacement in Fabry disease, with cardiomyocyte-relevant efficacy signals.

Juchem M, Oehlsen L, Ersoy S et al. · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · (2026) · View on PubMed ↗

Glucose-responsive probiotics for glycaemic modulation in mice and monkeys.

The study engineered an oral-deliverable, glucose-sensing probiotic living drug in mice and monkeys using a synthetic gene circuit with the glucose-responsive transcriptional regulator HexR to control glucose-lowering output. The key finding is that the engineered probiotic enables sense-and-respond regulation of diabetic blood glucose without requiring external control or transplantation of mammalian synthetic gene networks. This advances a potentially safer, implant-free approach for programmable diabetes therapy using engineered microbes.

Guan N, Kong D, Gao X et al. · Nature · (2026) · View on PubMed ↗

Mechanistic machine learning for prediction of prime editing outcomes.

The study developed OptiPrime, a mechanistic machine learning model to predict prime editing (PE) outcomes and improve pegRNA design efficiency. OptiPrime achieved state-of-the-art prediction accuracy for PE efficiency and extended predictions to PE3 nicking guide RNA and twinPE dual pegRNA outcomes, learning determinants involving mammalian mismatch repair (MMR) and enabling nomination of MMR-evasive silent edits that improve PE efficiency. This provides a practical computational tool to reduce experimental optimization and increase success rates for prime editing in mammalian systems.

Hsu A, Chen PJ, Li AH et al. · Nature biotechnology · (2026) · View on PubMed ↗

---

Gene regulation & chromatin/condensates (transcription looping, condensates, chromosome condensation, Rb/CDK4/6)

The eukaryote chromosome, a two-state system with interconversion by a volume phase transition.

The study examined how eukaryotic chromosome condensation can be modeled as a two-state physical system undergoing interconversion via a volume phase transition, focusing on ionic interactions between histone tails and DNA. The key finding is that chromosomes behave like ionic hydrogels with condensed and decondensed states controlled by histone acetylation/deacetylation that forms and breaks ionic contacts. This provides a mechanistic framework linking epigenetic histone modifications to large-scale chromosome physical state transitions.

Beel AJ, Matteï PJ, Kornberg RD · Science (New York, N.Y.) · (2026) · View on PubMed ↗

Circular Logic: Engineering Next-Generation Circular RNA Therapeutics for Precision Oncology.

This review studied how circular RNA (circRNA) topology can be engineered as next-generation therapeutics for precision oncology, focusing on endogenous and synthetic circRNAs across cancer contexts. It found that circRNAs’ covalently closed loop structure confers exonuclease resistance and sustained protein expression, and that topology should be treated as an active pharmacologic design variable rather than only a stability feature. This reframes circRNA therapeutic development for improved durability and potential biomarker utility in cancer diagnosis and longitudinal monitoring.

El-Sehrawy AAMA, Al-Ameer HJ, Rizaev J et al. · Biotechnology and bioengineering · (2026) · View on PubMed ↗

Rb-driven transcription limits its tumour-suppressive effects in breast cancer.

This study examined how pharmacologically activated retinoblastoma protein (Rb) after CDK4/6 inhibition remodels chromatin and transcription in hormone receptor-positive (HR+) breast cancer. The authors found that CDK4/6 inhibition redistributes hypophosphorylated Rb to promoters and enhancers, where Rb not only represses cell-cycle transcription but also unexpectedly promotes expression at non-canonical sites. This refines the mechanism of CDK4/6 inhibitor therapy by showing Rb has broader transcriptional roles beyond cell-cycle arrest.

Watt AC, Ahn A, Blyth C et al. · Nature · (2026) · View on PubMed ↗

hnRNPK condensates facilitate enhancer-promoter looping and RNA polymerase II recruitment.

The study identified hnRNPK as the RNA-binding protein that mediates enhancer–promoter looping by preferentially binding nascent RNAs from enhancer and promoter regions. It showed that hnRNPK forms phase-separated, cavity-containing condensates that encapsulate RNA polymerase II via the RPB3 subunit, facilitating chromatin looping and transcriptional activation. This links a specific condensate-forming factor to Pol II recruitment and enhancer–promoter communication, with implications for understanding transcription regulation in genome organization.

Ye R, Zhao H, Chen J et al. · Nature genetics · (2026) · View on PubMed ↗

---

RNA biology & surveillance (PUF proteins, exosome, RAN translation, viral RNA elements)

Proteome-wide identification of the druggable CRBN interactome.

This proteome-wide study mapped the druggable cereblon (CRBN) interactome for molecular glue degraders (MGDs) by using a highly parallel protein complementation assay (GluePCA) to detect MGD-induced CRBN binding without degradation. Using pomalidomide as the MGD, the authors identified ~210 zinc-finger proteins that bind CRBN-pomalidomide, including top binders already known to be degraded by dedicated MGDs. The work expands the CRBN “programmability” landscape, enabling more systematic discovery of new MGD substrates and rational design of next-generation targeted degraders.

Galli P, Xiao S, Meng Y et al. · Nature biotechnology · (2026) · View on PubMed ↗

Functional atlas of vertebrate viral RNA elements that stabilize RNA and enhance translation.

This study mapped vertebrate viral RNA elements that stabilize RNA and enhance translation by performing massively parallel reporter assays across ~200,000 genomic segments from 297 vertebrate-infecting viral genera. It identified many elements that increase RNA stability and translation via TENT4-mediated mixed tailing, organized into six subclasses across 19 viral genera, and also found TENT4-independent elements using alternative mechanisms. The results define convergent viral strategies for post-transcriptional control and provide candidate regulatory elements for further mechanistic and therapeutic exploration.

Seo JJ, Lee C, Lim D et al. · Cell · (2026) · View on PubMed ↗

RAN Translation-Coupled Decay of the C9orf72 GGGGCC Repeat Transcript by the RNA Exosome Suppresses Dipeptide Repeat Production.

This mechanistic study examined how the RNA exosome regulates repeat-associated non-AUG (RAN) translation of the C9orf72 GGGGCC hexanucleotide repeat expansion (C9-HRE) and thereby suppresses dipeptide-repeat (DPR) production. It found that RAN translation-coupled decay mediated by the RNA exosome reduces DPR output, indicating that aberrant RAN translation is monitored and degraded co-translationally. This provides a targetable RNA surveillance mechanism relevant to C9-ALS/FTD pathogenesis and potential therapeutic strategies aimed at limiting toxic DPRs.

Wu Y, Li L, Tian J et al. · International journal of molecular sciences · (2026) · View on PubMed ↗

PUF family RNA-binding proteins Puf1 and Puf2 promote transcript degradation in Toxoplasma gondii.

This study characterized the conserved PUF family RNA-binding proteins TgPuf1 and TgPuf2 in the parasite Toxoplasma gondii and tested their roles in mRNA stability and degradation. The authors identified TgPuf1/TgPuf2 expression and localization, demonstrated RNA-binding activity, and assessed essentiality during asexual stages (including functional perturbation experiments). By showing that PUF proteins promote transcript degradation, the study clarifies a key post-transcriptional regulatory mechanism that supports Toxoplasma life-cycle transitions and stress adaptation.

Khandavalli CR, Gurupwar R, Deshmukh AS · The Journal of biological chemistry · (2026) · View on PubMed ↗

---

Microbiome & infectious disease (EBV organoids, malaria chemovaccination, MRSA, antivirals, engineered probiotics)

Methicillin-resistant Staphylococcus aureus.

This Nature Reviews Disease Primer summarized the epidemiology, transmission, and disease spectrum of methicillin-resistant Staphylococcus aureus (MRSA) in humans, focusing on its transition from asymptomatic colonization to invasive infection. The key message is that MRSA causes a range of illnesses from skin/soft-tissue infections to invasive disease (bacteraemia, pneumonia, osteomyelitis, endocarditis) driven by virulence factors enabling adhesion, immune evasion, tissue invasion, and persistence. Clinically, the review highlights MRSA as a major antimicrobial-resistance threat and frames how understanding virulence and host-barrier disruption can guide prevention and treatment strategies.

Parsons JB, Westgeest AC, Conlon BP et al. · Nature reviews. Disease primers · (2026) · View on PubMed ↗

UV irradiation drives lineage-specific MITF-mediated transcription of PD-L1 to confer immune tolerance to UV-mutated melanocytes.

This mechanistic study investigated how UV irradiation drives immune tolerance to UV-mutated melanocytes by inducing lineage-specific MITF-mediated transcription of PD-L1 (CD274) in primary human melanocytes. It found that PD-L1 expression after UV exposure depends on microphthalmia-associated transcription factor (MITF), which directly binds a conserved upstream enhancer with functional E-box elements to activate PD-L1 transcription. Scientifically, this links a melanocyte lineage transcription factor to UV-induced immune evasion, suggesting potential targets to improve immune clearance of UV-mutated melanocytes.

Lo JA, Rachmin I, Flesher JL et al. · Immunity · (2026) · View on PubMed ↗

A tonsil organoid model reveals Epstein-Barr virus-infected germinal center B cell states during primary infection.

The study developed an Epstein-Barr virus (EBV) human tonsil organoid model to examine EBV-infected B cell states during primary infection in a lymphoid tissue microenvironment. EBV drove B cells toward germinal center-like phenotypes and transcriptomic profiling identified EBV-specific B cell gene programs, with B cell receptor repertoire analyses indicating most EBV-infected cells were clonally expanded (as suggested by the truncated abstract). This organoid system provides a clinically relevant platform to dissect EBV pathogenesis and antiviral responses in the context of secondary lymphoid tissue biology.

Mitul MT, Sun Y, Yates TB et al. · Proceedings of the National Academy of Sciences of the United States of America · (2026) · View on PubMed ↗

Dietary vitamin A restricts intestinal tuft cell differentiation.

The study examined how epithelial-intrinsic retinoic acid signaling and dietary vitamin A regulate tuft cell differentiation and anti-helminth immunity in mice and stem cell–derived intestinal organoids. Retinoic acid receptor–dependent signaling in the epithelium controlled tuft cell numbers, and administering retinoic acid to organoids reduced tuft cells while dietary vitamin A dynamically altered tuft cells in vivo in a tuft cell-dependent manner. These findings identify vitamin A/retinoic acid as a regulator of tuft cell homeostasis with implications for tuning mucosal immune responses against helminths.

Didriksen BJ, Eshleman EM, Rice T et al. · Cell reports · (2026) · View on PubMed ↗

Characterization of Sec14 Domain-Containing Proteins in the Malaria Parasite Plasmodium falciparum.

This study characterized six Sec14 domain-containing phosphatidylinositol transfer proteins (PfSec14-1/PF3D7_0626400 and five additional PfSec14-like proteins) in the malaria parasite Plasmodium falciparum to define their roles in phosphoinositide-dependent membrane trafficking. The authors report functional characterization consistent with Sec14-like proteins being important for phosphatidylinositol transfer and thereby for maintaining phosphoinositide regulation in P. falciparum. These findings identify Sec14-domain pathways as potential parasite vulnerabilities that could be exploited to develop new antimalarial therapeutics, especially in the context of artemisinin resistance.

Lauruol F, Šťastný D, Fernandez-Murray JP et al. · Molecular microbiology · (2026) · View on PubMed ↗

Maternal influences on infant gut microbiome and health.

This study used metagenomic sequencing of 4,526 longitudinal faecal samples from 714 mother–infant pairs in the Dutch Lifelines NEXT birth cohort to determine how maternal gut microbiome and early-life exposures shape infant gut microbiome and health. Maternal gut microbiome composition changed subtly during pregnancy and postpartum and was influenced by diet, infections, and pre-pregnancy smoking, while maternal microbiome served as a major reservoir for infant colonization (with additional profiling of breast milk and vaginal microbiomes). These findings clarify maternal determinants of early microbiome assembly, supporting microbiome-informed strategies to improve long-term health.

Sinha T, Brushett S, Fernández-Pato A et al. · Nature · (2026) · View on PubMed ↗

Shared principles of human and bacterial antiviral immunity.

This Review synthesizes evidence that antiviral immunity shares conserved principles across bacteria and humans, focusing on pathogen recognition, signal amplification, and effector mechanisms. The key message is that components of human antiviral immunity trace back to ancient bacterial pathways that defend against phage replication, providing a unifying framework for host–virus interactions. This conceptual integration can guide future mechanistic studies and therapeutic targeting of conserved antiviral pathways.

Kranzusch PJ · Nature · (2026) · 1 citations · View on PubMed ↗

---

Vaccines & infectious disease prevention (Ebola cross-protection, zoster vaccine, chemovaccination)

A boost for chemical vaccination against malaria.

The article discusses chemical vaccination strategies for malaria by targeting Plasmodium plasmepsin proteins with chemical inhibitors. The key finding is that inhibiting plasmepsins can function as a drug-based vaccination approach, offering a new route to induce protective immunity. This supports development of simpler, potentially more scalable “chemovaccination” concepts for malaria prevention.

Prudêncio M, Mota MM · Science (New York, N.Y.) · (2026) · View on PubMed ↗

‘Mismatched’ Ebola vaccine may soon be rolled out widely.

The piece evaluates emerging evidence on an Ebola vaccine for Ebola Zaire and whether it provides cross-protection against Bundibugyo. The key finding is that updated data suggest the Ebola Zaire vaccine may also protect against Bundibugyo. If confirmed in broader rollout contexts, this could expand vaccine utility across multiple Ebola species.

Kupferschmidt K · Science (New York, N.Y.) · (2026) · View on PubMed ↗

Chemovaccination with a late-liver-stage antimalarial induces durable immunity against malaria.

The study tested whether chemovaccination using a late-liver-stage Plasmodium falciparum–relevant approach could induce durable immunity in mice, using low-dose Plasmodium berghei sporozoite exposure combined with plasmepsin IX/ X (PMIX/X) inhibitors (WM382 or MK-7602) to generate chemo-attenuated liver merozoites (CALM). The key finding is that a single low-dose exposure plus PMIX/X inhibition induced sterile immunity lasting up to 21 months, mediated by anti-circumsporozoite protein (CSP) antibodies and CD8+ T cells including liver-resident memory subsets recognizing diverse antigens. This is clinically significant because it supports a potentially simpler, non–high-dose intravenous sporozoite vaccination strategy for long-lasting malaria protection.

Steel RWJ, Chua YC, Abdalla WAI et al. · Science (New York, N.Y.) · (2026) · View on PubMed ↗

Effectiveness of the recombinant zoster vaccine in adult patients with multiple sclerosis: A claims-based retrospective cohort study in the United States.

This US claims-based retrospective cohort study evaluated vaccine effectiveness of the recombinant zoster vaccine (RZV) in adults with multiple sclerosis (MS) aged ≥18 years who received two RZV doses between January 2018 and September 2023. Using matched vaccinated versus unvaccinated comparators and Cox models with inverse probability of treatment weighting, the study found RZV reduced the incidence of herpes zoster after the second dose. The results support RZV as an effective preventive intervention for herpes zoster in the MS population, informing immunization decisions in adults with chronic neurologic disease.

Kluberg SA, Mayer SE, Spence O et al. · Multiple sclerosis (Houndmills, Basingstoke, England) · (2026) · View on PubMed ↗

---

Methodology, imaging, and clinical trial design (single-cell/spatial omics, 3D pathology triage, cryo-ET, risk scores)

Recent advances in cryoelectron tomography and applications to parasitology.

This review summarized recent advances in cryo-electron tomography (cryo-ET) and how these developments are applied to parasitology. It highlighted improvements in sample preparation, data collection, and computational analysis that enable visualization of native ultrastructure in medically important parasites such as Toxoplasma gondii, Plasmodium falciparum, Trypanosoma brucei, Trypanosoma cruzi, Cryptosporidium parvum, and microsporidia. The scientific significance is that cryo-ET is increasingly enabling near-native structural cell biology insights that can inform mechanisms of parasite survival and potential intervention targets.

Coudray N, Ekiert DC, Bhabha G · Current opinion in structural biology · (2026) · View on PubMed ↗

Extracorporeal Shockwave Therapy in Pain Management - an In-Depth Narrative Review.

This narrative review synthesized mechanistic and clinical evidence for extracorporeal shockwave therapy (ESWT) across multiple chronic pain conditions, including tendinopathies, plantar fasciitis, osteoarthritis, and low back pain. It reports that recent trials and meta-analyses (notably from 2024) generally supported ESWT efficacy for several chronic pain indications. The review’s significance is to consolidate current mechanistic rationale and effectiveness data to guide clinical decision-making and future research on ESWT.

Ufondu W, Ogunsola O, Williams A et al. · Orthopedic reviews · (2026) · View on PubMed ↗ · Free PDF ↗

Long-Term Survival of Borna Disease Virus 1 (BoDV-1)-Encephalitis: An Exceptional Case with Valuable Insights for Pathophysiology and Disease Management.

This case report studied a long-term survivor of Borna disease virus 1 (BoDV-1) encephalitis to characterize distinctive clinical course, imaging findings, and pathophysiology relevant to management. It found that despite the typically fatal (sub)acute panencephalitis course, the patient survived long-term with notable MRI features (including vasogenic edema in basal ganglia and limbic regions) and a course that differed from the usual rapid decline. This provides rare real-world insights that may inform future diagnostic vigilance and therapeutic decision-making for BoDV-1 encephalitis.

Grabova D, Wilkens I, Klein M et al. · Infectious diseases and therapy · (2026) · View on PubMed ↗

Simultaneous single-cell profiling of chromatin, transcriptome and surface markers with OneCell CUT&Tag captures epigenomic reprogramming.

The study introduced OneCell CUT&Tag to simultaneously profile chromatin, full transcriptomes, and surface markers from individual cells with very low input (down to one cell) without metacell aggregation. Using this approach, the authors uncovered epigenomic priming of mammary basal cells and captured dynamics of basal-to-luminal transdifferentiation, linking epigenomic changes to transcriptional programs at single-cell resolution. This method enables integrated multi-omic mapping of rare cell states and lineage transitions with minimal cell numbers.

Schwager A, Moutaux E, Durand A et al. · Nature biotechnology · (2026) · View on PubMed ↗

Deep-learning triage of three-dimensional pathology datasets for comprehensive and efficient pathologist assessments.

The study developed TRICARE, a deep-learning triage framework to select high-risk 2D cross-sections from large 3D pathology datasets for efficient pathologist review. It found that TRICARE can identify which 2D sections within 3D tissue volumes warrant attention, enabling time-efficient assessments despite the massive scale of 3D pathology generated by techniques such as open-top light-sheet microscopy. Scientifically and clinically, this supports faster, more comprehensive evaluation of spatially heterogeneous tumors while reducing the workload barrier to adopting 3D pathology in practice.

Gao G, Yan R, Song AH et al. · Nature biomedical engineering · (2026) · View on PubMed ↗

Population-based genomic detection of childhood cancer predisposition using newborn dried blood spots.

This study evaluated population-based genomic detection of childhood cancer predisposition using targeted sequencing of 11 cancer predisposition genes from archived newborn dried blood spots in a Michigan birth cohort (1987–2020). It found pathogenic or likely-pathogenic germline variants in 6.8% of children who developed solid or CNS malignancies by age 8, with the most frequent genes including RB1 and TP53, and estimated an early-onset malignancy risk of approximately 1 in 27,000 newborns. Scientifically and clinically, it supports the feasibility of newborn screening for cancer predisposition and quantifies the yield and risk needed to guide implementation.

Diller L, Cherkerzian S, Cinelli AE et al. · Nature communications · (2026) · View on PubMed ↗

Faricimab for Polypoidal Choroidal Vasculopathy: 48-Week Results from the Phase 3b/4 SALWEEN Trial.

This phase 3b/4 SALWEEN trial evaluated faricimab in treatment-naïve adults aged ≥50 years with symptomatic polypoidal choroidal vasculopathy (PCV) in Asia, reporting 48-week efficacy and safety. Patients received faricimab 6 mg every 4 weeks during loading to week 12, then a treat-and-extend regimen (Q8W–Q16W through week 48) with interval adjustments based on protocol-defined disease activity measures such as central subfield thickness and best-corrected visual acuity. The 48-week results support faricimab’s clinical benefit and tolerability in PCV under a real-world-like treat-and-extend dosing strategy.

Cheung CMG, Lee WK, Chen SJ et al. · Ophthalmology. Retina · (2026) · View on PubMed ↗ · Free PDF ↗

---

---

Generated automatically on August 15, 2026 from PubMed’s trending articles. Summaries are AI-generated; always consult the original publication for clinical or research decisions.